QuidelOrtho Stock: Strong Buy on Q2 Growth

Oct 14, 2026

Bobby Quant Team

💡 Key Takeaway

QuidelOrtho's strong Q2 results, margin expansion, and cost-saving initiatives make it a compelling buy for growth-oriented investors.

QuidelOrtho's Q2 Performance and Strategic Progress

QuidelOrtho (QDEL) reported strong second-quarter results that beat expectations on key metrics. The company delivered 21% growth in EBITDA and expanded its margins to 20.5%, showcasing improved operational efficiency. Revenue growth was solid across its business segments, with Labs up 4% and Point of Care up 16%.

The company also made significant progress on its $50 million cost-saving initiatives, which are expected to further boost profitability in the coming quarters. These initiatives include streamlining operations and optimizing its product portfolio.

Following the earnings release, QuidelOrtho received a Zacks Rank #2 (Buy) rating, reflecting analysts' confidence in its growth prospects. The positive sentiment is echoed by similar ratings for peers like OPK (Strong Buy), GMED (Buy), and MMSI (Buy).

Overall, QuidelOrtho's Q2 performance demonstrates resilience and a clear path to sustainable growth, making it an attractive addition to portfolios focused on the healthcare sector.

What This Means for Me

If you hold QDEL, the strong Q2 results and positive outlook could lead to further stock appreciation, so consider holding or adding to your position. Investors with exposure to the medical diagnostics sector may benefit from the overall positive sentiment, as peers like OPK, GMED, and MMSI also show strong fundamentals. However, be mindful of potential regulatory changes and competitive pressures that could impact the sector.

Why QuidelOrtho's Q2 Results Matter for Investors

QuidelOrtho's strong Q2 results are a positive signal for the stock, as they indicate the company is executing well on its growth strategy. The 21% EBITDA growth and margin expansion to 20.5% suggest that QuidelOrtho is becoming more profitable, which could lead to higher earnings and a higher stock price over time.

The revenue growth in both Labs and Point of Care segments shows that demand for QuidelOrtho's products remains robust. The Point of Care segment, in particular, grew 16%, which is impressive and highlights the company's strength in rapid diagnostic testing.

The progress on cost-saving initiatives is also crucial. By reducing costs, QuidelOrtho can improve its bottom line even if revenue growth slows. This provides a cushion against economic uncertainties and enhances the company's ability to invest in future growth.

Compared to peers like OPK, GMED, and MMSI, QuidelOrtho's valuation may still be attractive. With a Zacks Rank #2 (Buy), it offers a balanced risk-reward profile for investors seeking exposure to the medical diagnostics sector.

Stock to Watch

Stocks	Impact	Analysis
GMED	Positive	Zacks Rank #2 with consistent earnings beats and long-term growth rate of 12.4%, benefiting from sector tailwinds.
MMSI	Positive	Zacks Rank #2 with strong Q2 results and long-term growth rate of 10.4%, supported by demand for medical devices.

Source: Zacks Investment Research
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.